Clinical Trials Directory

Trials / Unknown

UnknownNCT05666765

Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris

Comparative Study Between the Effect of Isotretinoin, Silymarin and Their Combination in the Treatment of Patients With Acne Vulgaris

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the effects of isotretinoin and silymarin or both in treatment of acne and their effects on the level of IGF-1, SAA1 and malondialdehyde (MDA) in acne patients.

Detailed description

Acne vulgaris, a common and chronic disorder of the pilosebaceous unit, affects up to 85% of adolescent and young adults. The pathogenesis of acne is multifactorial. Traditionally, four distinct processes were believed to play critical roles: increased sebum production, alteration of keratinization processes leading to comedone formation, follicular colonization by Propionibacterium acnes (P.acnes) and inflammatory mediators around pilosebaceous unit. Orally administered isotretinoin is currently the only agent that can affect all four main factors implicated in acne. Serum insulin-like growth factor -1(IGF)-1 is a polypeptide hormone that has effects on sebocyte differentiation and proliferation. It leads to lipogenesis, and synthesis of inflammatory cytokines. IGF-1 also stimulates androgen synthesis leading to overproduction of sebum. Propionibacterium acnes can increase the release of serum amyloid A1 (SAA1) .There is significant elevation of SAA1 in patients with acne, with a positive correlation with its severity. Oxidative stress plays a role in the pathogenesis of acne in part due to the generation of reactive oxygen species (ROS) in response to infection by the bacterium Propionibacterium acnes, which colonizes the skin and grows in plugged hair follicles, thus attracting inflammatory cells, mainly neutrophils. These in turn secrete inflammatory mediators and generate ROS, which augments the inflammatory response and tissue damage. Silymarin, the main active component of milk thistle consists of a mixture of flavonolignans and flavonoid taxifolin. Silymarin acts as a hepatoprotective, anticancer, anti-inflammatory and immunomodulatory agent. Silymarin acts as a free radical scavenger, stabilizes the plasma membrane and reduces the production of inflammatory mediators produced by P. acnes, and scavenges the released free radicals.

Conditions

Interventions

TypeNameDescription
DRUGIsotretinoin ,silymarin20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.

Timeline

Start date
2023-01-01
Primary completion
2023-11-01
Completion
2024-01-01
First posted
2022-12-28
Last updated
2022-12-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05666765. Inclusion in this directory is not an endorsement.